TABLE I.
Demographics and medical history of patients with suspected anaphylaxis to COVID-19 vaccine
| Characteristic | All (n = 60) | Moderna (n = 15) | Pfizer-BioNTech (n = 45) | P∗ |
|---|---|---|---|---|
| Reaction with first dose | 48 (80) | 10 (67) | 38 (84) | .15 |
| Age, y (means ± SDs) | 41 ± 18 | 40 ± 22 | 41 ± 17 | .86 |
| Female | 51 (85) | 10 (67) | 41 (91) | .036 |
| Race | .86 | |||
| American Indian or Alaska Native | 1 (2) | 0 | 1 (2) | |
| Asian | 2 (3) | 1 (7) | 1 (2) | |
| Black | 4 (7) | 1 (7) | 3 (7) | |
| Latino | 1 (2) | 0 | 1 (2) | |
| Unknown | 3 (5) | 1 (7) | 2 (4) | |
| White | 49 (82) | 12 (80) | 37 (82) | |
| History of atopic disease | 35 (58) | 7 (47) | 28 (62) | .29 |
| Asthma | 25 (42) | 4 (27) | 21 (47) | |
| Allergic rhinitis | 19 (32) | 4 (27) | 15 (33) | |
| Contact dermatitis | 4 (7) | 2 (13) | 2 (4) | |
| Eczema | 4 (7) | 1 (7) | 3 (7) | |
| History of anaphylaxis | 27 (45) | 2 (13) | 25 (56) | .004 |
| Medication | 11 (18) | 0 | 11 (24) | |
| Food | 10 (17) | 2 (13) | 8 (18) | |
| Venom | 4 (7) | 0 | 4 (9) | |
| Idiopathic | 2 (3) | 0 | 2 (4) | |
| History of chronic urticaria | 5 (8) | 0 | 5 (11) | .32 |
Data are shown as n (%) unless specified.
Italic indicates statistical significance.
∗
χ2 or t test, as indicated.